Heli Leppikangas
Research Subjects
Heli Leppikangas has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
L. Lindgren
2 shared publicationsE. Ruokonen
Department of Intensive Care, Kuopio University Hospital, Finland
1 shared publication- Esko Ruokonen
Department of Intensive Care, Kuopio University Hospital, Finland
1 shared publication J. J. Tenhunen
Critical Care Medicine Research Group, Departments of Critical Care Medicine, Anesthesiology and Vascular Surgery, Tampere University Hospital, Tampere, Finland
1 shared publicationJ.‐P. Salenius
Critical Care Medicine Research Group, Departments of Critical Care Medicine, Anesthesiology and Vascular Surgery, Tampere University Hospital, Tampere, Finland
1 shared publication- Jarkko Magga
Department of Intensive Care, Kuopio University Hospital, Kuopio, Finland
1 shared publication
Latest Publications
- 1 December 2011
- Published by Wolters Kluwer Health in Survey of Anesthesiology
- Vol. 55 (6) , 263
Preoperative Levosimendan Infusion in Combined Aortic Valve and Coronary Artery Bypass Surgery
- 1 December 2011
- Published by Wolters Kluwer Health in Survey of Anesthesiology
- Vol. 55 (6) , 263
Preoperative Levosimendan Infusion in Combined Aortic Valve and Coronary Artery Bypass Surgery
- Open Access
- 1 August 2011
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 107 (2) , 277
Reply from the authors
Editor—We would like to thank Dr Guarracino and Dr Tritapepe for their interest in and criticism on our article addressing the use of preoperative levosimendan in combined aortic valve and coronary bypass surgery.1 Currently, levosimendan is indicated for i.v. use in hospitalized patients with acutely decompensated heart failure (ADHF). The mechanism of action and current literature suggest that the therapeutic potential of levosimendan may not be limited only to ADHF patients. We are happy to share the interest in studying levosimendan in new clinical settings with Dr Guarracino and Dr Tritapepe.
- 1 August 2011
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 107 (2) , 277
Open AccessReply from the authors
Editor—We would like to thank Dr Guarracino and Dr Tritapepe for their interest in and criticism on our article addressing the use of preoperative levosimendan in combined aortic valve and coronary bypass surgery.1 Currently, levosimendan is indicated for i.v. use in hospitalized patients with acutely decompensated heart failure (ADHF). The mechanism of action and current literature suggest that the therapeutic potential of levosimendan may not be limited only to ADHF patients. We are happy to share the interest in studying levosimendan in new clinical settings with Dr Guarracino and Dr Tritapepe.
- 1 March 2011
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 106 (3) , 298-304
Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery
Cardiopulmonary bypass may have detrimental effects on intestinal function and decrease the concentrations of the active, long-acting metabolites of levosimendan, an inodilator used to improve cardiac function. The aim of this study was to evaluate the haemodynamic effects of preoperative levosimendan in patients undergoing high-risk cardiac surgery. Twenty-four patients were randomized to receive levosimendan (12 µg bolus followed by an infusion of 0.2 µg kg(-1) min(-1)) or a placebo 24 h before surgery. The inclusion criteria were left ventricular ejection fraction (LVEF) 12 mm. Haemodynamics were recorded every hour for 24 h (pulmonary artery catheter) and daily until postoperative day 4 (whole-body impedance cardiography). Doppler echocardiography with tissue Doppler imaging was used to assess systolic and diastolic cardiac function. The cardiac index (CI) and stroke volume index (SI) were higher in the levosimendan group (LG) for the 4 day postoperative period (P<0.05); on the fourth postoperative day, the CI was 3.0 litre m(-2) min(-1) in the LG compared with 2.4 litre m(-2) min(-1) in the control group (CG) and the SI was 30 vs 25 ml m(-2), respectively. The LVEF measured at baseline and on the fourth postoperative morning decreased in the CG, but was maintained in the LG. Levosimendan improved haemodynamics compared with a placebo in patients undergoing high-risk cardiac surgery. The concentrations of levosimendan's metabolites were higher compared with earlier studies using perioperative dosing.
- 1 March 2011
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 106 (3) , 298-304
Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery
Cardiopulmonary bypass may have detrimental effects on intestinal function and decrease the concentrations of the active, long-acting metabolites of levosimendan, an inodilator used to improve cardiac function. The aim of this study was to evaluate the haemodynamic effects of preoperative levosimendan in patients undergoing high-risk cardiac surgery. Twenty-four patients were randomized to receive levosimendan (12 µg bolus followed by an infusion of 0.2 µg kg(-1) min(-1)) or a placebo 24 h before surgery. The inclusion criteria were left ventricular ejection fraction (LVEF) 12 mm. Haemodynamics were recorded every hour for 24 h (pulmonary artery catheter) and daily until postoperative day 4 (whole-body impedance cardiography). Doppler echocardiography with tissue Doppler imaging was used to assess systolic and diastolic cardiac function. The cardiac index (CI) and stroke volume index (SI) were higher in the levosimendan group (LG) for the 4 day postoperative period (P<0.05); on the fourth postoperative day, the CI was 3.0 litre m(-2) min(-1) in the LG compared with 2.4 litre m(-2) min(-1) in the control group (CG) and the SI was 30 vs 25 ml m(-2), respectively. The LVEF measured at baseline and on the fourth postoperative morning decreased in the CG, but was maintained in the LG. Levosimendan improved haemodynamics compared with a placebo in patients undergoing high-risk cardiac surgery. The concentrations of levosimendan's metabolites were higher compared with earlier studies using perioperative dosing.
- Open Access
- 1 January 2010
- Published by Springer Nature in Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine
- Vol. 18 (1) , 12
Effect of levosimendan in experimental verapamil- induced myocardial depression
Calcium antagonist overdose can cause severe deterioration of hemodynamics unresponsible to treatment with beta adrenergic inotropes. The aim of the study was to evaluate in an experimental model the effects of levosimendan during severe calcium antagonist intoxication.
- 1 January 2010
- Published by Springer Nature in Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine
- Vol. 18 (1) , 12
Open AccessEffect of levosimendan in experimental verapamil- induced myocardial depression
Calcium antagonist overdose can cause severe deterioration of hemodynamics unresponsible to treatment with beta adrenergic inotropes. The aim of the study was to evaluate in an experimental model the effects of levosimendan during severe calcium antagonist intoxication.
- 28 June 2008
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 52 (6) , 785-792
Effects of levosimendan on indocyanine green plasma disappearance rate and the gastric mucosal–arterial pCO2 gradient in abdominal aortic aneurysm surgery
Levosimendan has a dual mechanism of action: it improves myocardial contractility and causes vasodilatation without increasing myocardial oxygen demand. In a laboratory setting, it selectively increases gastric mucosal oxygenation in particular and splanchnic perfusion in general. The aim of our study was to describe the effects of levosimendan on systemic and splanchnic circulation during and after abdominal aortic surgery. Twenty abdominal aortic aneurysm surgery patients were randomized to receive either levosimendan (n=10) or placebo (n=10) in a double-blinded manner. Both the mode of anaesthesia and the surgical procedures were performed according to the local guidelines. Automatic gas tonometry was used to measure the gastric mucosal partial pressure of carbon dioxide. Systemic indocyanine green clearance plasma disappearance rate (ICG-PDR) was used to estimate the total splanchnic blood flow. The immediate post-operative recovery was uneventful in the two groups with a comparable, overnight length of stay in the intensive care unit. Cumulative doses of additional vasoactive drugs were comparable between the groups, with a tendency towards a higher cumulative dose of noradrenaline in the levosimendan group. After aortic clamping, the cardiac index was higher [4(3.8-4.7) l/min/m(2) vs. 2.6(2.3-3.6) l/min/m(2); P<0.05] and the gastric mucosal-arterial pCO(2) gradient was lower in levosimendan-treated patients [0.9(0.6-1.2) kPa vs. 1.7(1.2-2.1) kPa; (P<0.05)]. However, the total splanchnic blood flow, estimated by ICG-PDR, was comparable [29(21-29)% vs. 20(19-25)%; NS]. Organ dysfunction scores (sequential organ dysfunction assessment) were similar between the groups on the fifth post-operative day. Levosimendan favours gastric perfusion but appears not to have a major effect on total splanchnic perfusion in patients undergoing an elective aortic aneurysm operation.
- 28 June 2008
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 52 (6) , 785-792
Effects of levosimendan on indocyanine green plasma disappearance rate and the gastric mucosal–arterial pCO2 gradient in abdominal aortic aneurysm surgery
Levosimendan has a dual mechanism of action: it improves myocardial contractility and causes vasodilatation without increasing myocardial oxygen demand. In a laboratory setting, it selectively increases gastric mucosal oxygenation in particular and splanchnic perfusion in general. The aim of our study was to describe the effects of levosimendan on systemic and splanchnic circulation during and after abdominal aortic surgery. Twenty abdominal aortic aneurysm surgery patients were randomized to receive either levosimendan (n=10) or placebo (n=10) in a double-blinded manner. Both the mode of anaesthesia and the surgical procedures were performed according to the local guidelines. Automatic gas tonometry was used to measure the gastric mucosal partial pressure of carbon dioxide. Systemic indocyanine green clearance plasma disappearance rate (ICG-PDR) was used to estimate the total splanchnic blood flow. The immediate post-operative recovery was uneventful in the two groups with a comparable, overnight length of stay in the intensive care unit. Cumulative doses of additional vasoactive drugs were comparable between the groups, with a tendency towards a higher cumulative dose of noradrenaline in the levosimendan group. After aortic clamping, the cardiac index was higher [4(3.8-4.7) l/min/m(2) vs. 2.6(2.3-3.6) l/min/m(2); P<0.05] and the gastric mucosal-arterial pCO(2) gradient was lower in levosimendan-treated patients [0.9(0.6-1.2) kPa vs. 1.7(1.2-2.1) kPa; (P<0.05)]. However, the total splanchnic blood flow, estimated by ICG-PDR, was comparable [29(21-29)% vs. 20(19-25)%; NS]. Organ dysfunction scores (sequential organ dysfunction assessment) were similar between the groups on the fifth post-operative day. Levosimendan favours gastric perfusion but appears not to have a major effect on total splanchnic perfusion in patients undergoing an elective aortic aneurysm operation.